{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:03:32Z","timestamp":1793361812075,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T00:00:00Z","timestamp":1654905600000},"content-version":"am","delay-in-days":314,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.clim.2021.108774","type":"journal-article","created":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T13:14:07Z","timestamp":1623071647000},"page":"108774","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Combining multi-antigenic immunodot with indirect immunofluorescence on HEp-2 cells improves the diagnosis of systemic sclerosis"],"prefix":"10.1016","volume":"229","author":[{"given":"Chlo\u00e9","family":"Bost","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Fortenfant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Blancher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e9gory","family":"Pugnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Renaudineau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2021.108774_bb0005","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat. Rev. Dis. Prim"},{"key":"10.1016\/j.clim.2021.108774_bb0010","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/7a52649c-0942-4bd8-a5d3-3cdacca03cd8","article-title":"Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy","volume":"7","author":"Gorlova","year":"2011","journal-title":"PLoS Genet."},{"key":"10.1016\/j.clim.2021.108774_bb0015","doi-asserted-by":"crossref","first-page":"735","DOI":"10.2340\/00015555-2980","article-title":"Clinical characteristics of pruritus in systemic sclerosis vary according to the autoimmune subtype","volume":"98","author":"Gourier","year":"2018","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.clim.2021.108774_bb0020","doi-asserted-by":"crossref","first-page":"S222","DOI":"10.5152\/eurjrheum.2020.19116","article-title":"Systemic sclerosis: to subset or not to subset, that is the question","volume":"7","author":"Johnson","year":"2020","journal-title":"Eur. J. Rheumatol."},{"key":"10.1016\/j.clim.2021.108774_bb0025","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.rdc.2015.04.003","article-title":"New classification criteria for systemic sclerosis (scleroderma)","volume":"41","author":"Pope","year":"2015","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"10.1016\/j.clim.2021.108774_bb0030","first-page":"2019","article-title":"Anti-Ku syndrome with elevated CK: association with myocardial involvement in systemic sclerosis","volume":"0","author":"Campochiaro","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2021.108774_bb0035","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1136\/annrheumdis-2018-212999","article-title":"Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer","volume":"77","author":"Igusa","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2021.108774_bb0040","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1080\/08916934.2017.1357699","article-title":"Disease-related autoantibody profile in patients with systemic sclerosis","volume":"50","author":"Liaskos","year":"2017","journal-title":"Autoimmunity."},{"key":"10.1016\/j.clim.2021.108774_bb0045","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/art.39432","article-title":"Characteristics and survival of anti-U1 RNP antibody-positive patients with connective tissue disease-associated pulmonary arterial hypertension","volume":"68","author":"Sobanski","year":"2016","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2021.108774_bb0050","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12016-018-8718-8","article-title":"Antinuclear antibodies in systemic sclerosis: an update","volume":"58","author":"Stochmal","year":"2020","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.clim.2021.108774_bb0055","doi-asserted-by":"crossref","first-page":"542","DOI":"10.3109\/08916934.2015.1077231","article-title":"Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects","volume":"48","author":"Wodkowski","year":"2015","journal-title":"Autoimmunity"},{"key":"10.1016\/j.clim.2021.108774_bb0060","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"Classification criteria for systemic sclerosis: An American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"Van Den Hoogen","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2021.108774_bb0065","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1515\/cclm-2018-0188","article-title":"International consensus on antinuclear antibody patterns: definition of the AC-29 pattern associated with antibodies to DNA topoisomerase i","volume":"56","author":"Andrade","year":"2018","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.clim.2021.108774_bb0070","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1177\/0961203316640920","article-title":"Report on the second international consensus on ANA pattern (ICAP) workshop in Dresden 2015","volume":"25","author":"Chan","year":"2016","journal-title":"Lupus."},{"key":"10.1016\/j.clim.2021.108774_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-015-0594-5","article-title":"Application of the 2013 ACR\/EULAR classification criteria for systemic sclerosis to patients with Raynaud\u2019s phenomenon","volume":"17","author":"Park","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.clim.2021.108774_bb0080","doi-asserted-by":"crossref","first-page":"322","DOI":"10.5606\/ArchRheumatol.2018.6630","article-title":"Clinical characteristics of systemic sclerosis with interstitial lung disease","volume":"33","author":"Jung","year":"2018","journal-title":"Arch. Rheumatol."},{"key":"10.1016\/j.clim.2021.108774_bb0085","doi-asserted-by":"crossref","first-page":"113","DOI":"10.4236\/ojra.2013.32017","article-title":"Associations with organ involvement and autoantibodies in systemic sclerosis: results from the Canadian scleroderma research group (CSRG)","volume":"3","author":"Tangri","year":"2013","journal-title":"Open J. Rheumatol. Autoimmune Dis."},{"key":"10.1016\/j.clim.2021.108774_bb0090","first-page":"176","article-title":"Quel est l\u2019int\u00e9r\u00eat de la recherche des anticorps anti-nucl\u00e9olaires dans la scl\u00e9rodermie syst\u00e9mique\u00a0?","volume":"26","author":"Comacle","year":"2011","journal-title":"Immuno-Analyse Biol. Spec."},{"key":"10.1016\/j.clim.2021.108774_bb0095","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.autrev.2010.09.005","article-title":"Clinical and laboratory aspects of Ro\/SSA-52 autoantibodies","volume":"10","author":"Defendenti","year":"2011","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.clim.2021.108774_bb0100","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.autrev.2015.10.001","article-title":"Anti-centromere protein a antibodies in systemic sclerosis: significance and origin","volume":"15","author":"Perosa","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.clim.2021.108774_bb0105","first-page":"1","article-title":"Anti-centromere antibodies target centromere-kinetochore macrocomplex: a comprehensive autoantigen profiling","volume":"0","author":"Kajio","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2021.108774_bb0110","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1136\/ard.61.2.121","article-title":"Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis","volume":"61","author":"Dick","year":"2002","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2021.108774_bb0115","doi-asserted-by":"crossref","first-page":"R172","DOI":"10.1186\/ar3495","article-title":"Frequency of disease-associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: Correlation with characteristic clinical features","volume":"13","author":"Mierau","year":"2011","journal-title":"Arthritis Res. Ther"},{"key":"10.1016\/j.clim.2021.108774_bb0120","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1136\/annrheumdis-2019-215862","article-title":"Antigen-driven selection of antibodies against SSA, SSB and the centromere complex\u2019, including a novel antigen, MIS12 complex, in human salivary glands","volume":"79","author":"Takeshita","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2021.108774_bb0125","doi-asserted-by":"crossref","first-page":"10514","DOI":"10.1016\/S0021-9258(19)86738-8","article-title":"Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma","volume":"254","author":"Douvas","year":"1979","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.clim.2021.108774_bb0130","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1172\/JCI111767","article-title":"Scl-86, a marker antigen for diffuse scleroderma","volume":"75","author":"van Venrooij","year":"1985","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.clim.2021.108774_bb0135","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1002\/art.21147","article-title":"Involvement of lysosomal cathepsins in the cleavage of DNA topoisomerase I during necrotic cell death","volume":"52","author":"Pacheco","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2021.108774_bb0140","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.4049\/jimmunol.173.4.2834","article-title":"Molecular recognition patterns of serum anti-DNA topoisomerase I antibody in systemic sclerosis","volume":"173","author":"Hu","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2021.108774_bb0145","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1515\/cclm-2015-0083","article-title":"Second generation analysis of antinuclear antibody (ANA) by combination of screening and confirmatory testing","volume":"53","author":"Scholz","year":"2015","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.clim.2021.108774_bb0150","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1196\/annals.1398.026","article-title":"Antitopoisomerase 1 antibodies in systemic sclerosis: how to improve the detection?","volume":"1109","author":"Tamby","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.clim.2021.108774_bb0155","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1007\/s10067-020-04973-0","article-title":"Performance evaluation of a commercial line blot assay system for detection of myositis- and systemic sclerosis-related autoantibodies","volume":"39","author":"Hamaguchi","year":"2020","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.clim.2021.108774_bb0160","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/rheumatology\/40.10.1157","article-title":"Anti-fibrillarin antibodies in systemic sclerosis","volume":"40","author":"Tormey","year":"2001","journal-title":"Rheumatology."},{"key":"10.1016\/j.clim.2021.108774_bb0165","first-page":"43","article-title":"Association of antinuclear and antinucleolar antibodies in progressive systemic sclerosis","volume":"48","author":"Bernstein","year":"1982","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.clim.2021.108774_bb0170","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.autrev.2012.05.011","article-title":"Autoantibodies in systemic sclerosis","volume":"12","author":"Mehra","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.clim.2021.108774_bb0175","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/art.24409","article-title":"Anti-U3 RNP autoantibodies in systemic sclerosis","volume":"60","author":"Aggarwal","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2021.108774_bb0180","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s12026-015-8710-9","article-title":"Detection of anti-U3-RNP\/fibrillarin IgG antibodies by line immunoblot assay has comparable clinical significance to immunoprecipitation testing in systemic sclerosis","volume":"64","author":"Peterson","year":"2016","journal-title":"Immunol. Res."},{"key":"10.1016\/j.clim.2021.108774_bb0185","first-page":"80","article-title":"The clinical relevance of autoantibodies in scleroderma","volume":"5","author":"Ho","year":"2003","journal-title":"Arthritis Res. Ther."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152166162100111X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152166162100111X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:04:39Z","timestamp":1761494679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152166162100111X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":37,"alternative-id":["S152166162100111X"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2021.108774","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combining multi-antigenic immunodot with indirect immunofluorescence on HEp-2 cells improves the diagnosis of systemic sclerosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2021.108774","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108774"}}